Fentanyl

Generic Name
Fentanyl
Brand Names
Abstral, Actiq, Duragesic, Effentora, Fentora, Instanyl, Lazanda, Sublimaze, Subsys, PecFent
Drug Type
Small Molecule
Chemical Formula
C22H28N2O
CAS Number
437-38-7
Unique Ingredient Identifier
UF599785JZ
Background

Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like morphine and oxycodone.
...

Indication

Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia. These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia. Finally, fentanyl intravenous or intramuscular injections are u...

Associated Conditions
Cancer Related Pain (Breakthrough Pain), Severe, Chronic Pain
Associated Therapies
Anesthetic premedication therapy, Anesthetics Agent, General Anesthesia, Induction of anesthesia therapy, Maintenance of anesthesia therapy, Regional Anesthesia therapy
Clinical Trials
Related News
painnewsnetwork.org
·

Cancer Patients Abandoned When Fentanyl Painkillers Discontinued

Teva Pharmaceuticals discontinued TIRF fentanyl meds, leaving cancer patients in severe pain without effective alternatives. The FDA notified patients and prescribers of the discontinuation by September 30. TIRF meds, like Actiq and Fentora, are crucial for breakthrough pain but face criticism and low enrollment in the FDA's REMS program. Teva's decision likely stems from opioid litigation costs and a strategic focus on more profitable drugs, leaving patients like Anthony struggling for relief.
lawdragon.com
·

Michael Wernke is Fighting Corporate Malfeasance – and Winning Big for Investors

Pomerantz partner Michael Wernke led high-profile securities fraud cases against Teva Pharmaceuticals, Y-mAbs Therapeutics, and Nikola Corp., securing favorable settlements and refining legal strategies for future cases.
ca.news.yahoo.com
·

Dangerous fentanyl 'candy' is finally off the market. It fueled the opioid crisis

Prescription fentanyl lollipops, lozenges, and mouth sprays were withdrawn from the U.S. market on Sept. 30. These transmucosal immediate-release fentanyl (TIRF) products, highly potent and addictive, were initially approved for hospital use in 1993 and later for cancer-related breakthrough pain. However, they were widely misused for chronic noncancer pain, leading to significant safety risks and fines for illegal marketing. The withdrawal is a positive step, but their approval was a regulatory failure.
islandernews.com
·

FDA Says Drug Makers Will Stop Producing Fentanyl 'Lollipops'

FDA announces drug makers will stop producing fentanyl lollipops and similar TIRF medications, used for breakthrough pain in opioid-tolerant cancer patients, following aggressive marketing and lawsuits. Teva Pharmaceuticals, which acquired Cephalon in 2011, will cease sales on Sept. 30.
medicalxpress.com
·

FDA says drug makers will stop producing fentanyl 'lollipops'

FDA announces drug makers will stop producing fentanyl lollipops and similar products, used for breakthrough pain in cancer patients tolerant to opioid therapy, following decades of lawsuits and aggressive marketing.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy